The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis
Open accessAbstract
Introduction: Fungal sepsis is an increasingly common problem in intensive care unit patients.Mortality from fungal sepsis remains high despite antimicrobial therapy that is highly active against most fungal pathogens, a finding consistent with defective host immunity that is present in many patients with disseminated fungemia.One recently recognized immunologic defect that occurs in patients with sepsis is T cell "exhaustion" due to increased expression of programmed cell death -1 (PD-1).This study tested the ability of anti-PD-1 and anti-programmed cell death ligand -1 (anti-PD-L1) antagonistic antibodies to improve survival and reverse sepsis-induced immunosuppression in two mouse models of fungal sepsis. Methods: Fungal sepsis was induced in mice using two different models of infection, that is, primary fungal sepsis and secondary fungal sepsis occurring after sub-lethal cecal ligation and puncture (CLP).Anti-PD-1 and anti-PD-L1 were administered 24 to 48 h after fungal infection and effects on survival, interferon gamma production, and MHC II expression were examined. Results: Anti-PD-1 and anti-PD-L1 antibodies were highly effective at improving survival in primary and secondary fungal sepsis.Both antibodies reversed sepsis-induced suppression of interferon gamma and increased expression of MHC II on antigen presenting cells.Blockade of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a second negative co-stimulatory molecule that is up-regulated in sepsis and acts like PD-1 to suppress T cell function, also improved survival in fungal sepsis. Conclusions: Immuno-adjuvant therapy with anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies reverse sepsis-induced immunosuppression and improve survival in fungal sepsis.The present results are consistent with previous studies showing that blockade of PD-1 and CTLA-4 improves survival in bacterial sepsis.Thus, immuno-adjuvant therapy represents a novel approach to sepsis and may have broad applicability in the disorder.Given the relative safety of anti-PD-1 antibody in cancer clinical trials to date, therapy with anti-PD-1 in patients with life-threatening sepsis who have demonstrable immunosuppression should be strongly considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationAngus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107000-00002 · Cited by 8,503
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure
Boomer, J. S., To, K., Chang, K. C., Takasu, O., Osborne, D. F., Walton, A. H., Bricker, T. L., Jarman, S. D., Kreisel, D., Krupnick, A. S., et al. (2011) · JAMA · doi:10.1001/jama.2011.1829 · Cited by 1,781
Self-citationThe function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
Self-citationEmerging opportunistic yeast infections
Miceli, M. H., Díaz, J. A., & Lee, S. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70218-8 · Cited by 811
Chen, D. S., Irving, B. A., & Hodi, F. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1362 · Cited by 654
Delano, M. J., Scumpia, P. O., Weinstein, J. S., Coco, D., Nagaraj, S., Kelly-Scumpia, K. M., O'Malley, K. A., Wynn, J. L., Antonenko, S., Al-Quran, S. Z., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062602 · Cited by 652
The sepsis seesaw: tilting toward immunosuppression
Hotchkiss, R. S., Coopersmith, C. M., McDunn, J. E., & Ferguson, T. A. (2009) · Nature Medicine · doi:10.1038/nm0509-496 · Cited by 574
Self-citationDurable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545
Huang, X., Venet, F., Wang, Y. L., Lepape, A., Yuan, Z., Chen, Y., Swan, R., Kherouf, H., Monneret, G., Chung, C.-S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809422106 · Cited by 515
Said, E. A., Dupuy, F. P., Trautmann, L., Zhang, Y., Shi, Y., El-Far, M., Hill, B. J., Noto, A., Ancuta, P., Peretz, Y., et al. (2010) · Nature Medicine · doi:10.1038/nm.2106 · Cited by 481
Murphy, S. L. (2000) · PubMed · Cited by 429
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Compensatory anti-inflammatory response syndrome
Cavaillon, J.-M., & Adib-Conquy, M. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-07-0421 · Cited by 356
Monitoring Immune Dysfunctions in the Septic Patient: A New Skin for the Old Ceremony
Monneret, G., Venet, F., Pachot, A., & Lepape, A. (2008) · Molecular Medicine · doi:10.2119/2007-00102.monneret · Cited by 340
Guignant, C., Lepape, A., Huang, X., Kherouf, H., Denis, L., Poitevin, F., Malcus, C., Chéron, A., Allaouchiche, B., Gueyffier, F., et al. (2011) · Critical Care · doi:10.1186/cc10112 · Cited by 325
Zhang, Y., Zhou, Y., Lou, J., Li, J., Bo, L., Zhu, K., Wan, X., Deng, X., & Cai, Z. (2010) · Critical Care · doi:10.1186/cc9354 · Cited by 308
Role of PD-1 in Regulating T-Cell Immunity
Jin, H.-T., Ahmed, R., & Okazaki, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_116 · Cited by 305
Brahmamdam, P., Inoue, S., Unsinger, J., Chang, K. C., McDunn, J. E., & Hotchkiss, R. S. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0110037 · Cited by 305
Self-citationJarvis, J. N., Meintjes, G., Rebe, K., Williams, G. N., Bicanic, T., Williams, A., Schutz, C., Bekker, L.-G., Wood, R., & Harrison, T. S. (2012) · AIDS · doi:10.1097/qad.0b013e3283536a93 · Cited by 290
Wong, R. M., Scotland, R. R., Lau, R. L., Wang, C., Korman, A. J., Kast, W. M., & Weber, J. S. (2007) · International Immunology · doi:10.1093/intimm/dxm091 · Cited by 231
Self-citationCharacterization and Modulation of the Immunosuppressive Phase of Sepsis
Muenzer, J. T., Davis, C. G., Chang, K., Schmidt, R. E., Dunne, W. M., Coopersmith, C. M., & Hotchkiss, R. S. (2010) · Infection and Immunity · doi:10.1128/iai.01213-09 · Cited by 203
Self-citationImmunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure
Boomer, J. S., To, K., Chang, K. C., Takasu, O., Osborne, D. F., Walton, A. H., Bricker, T. L., Jarman, S. D., Kreisel, D., Krupnick, A. S., et al. (2012) · Survey of Anesthesiology · doi:10.1097/sa.0b013e3182751ec1 · Cited by 167
Self-citationDose-Dependent Effect of Anti-CTLA-4 on Survival in Sepsis
Inoue, S., Bo, L., Bian, J., Unsinger, J., Chang, K. C., & Hotchkiss, R. S. (2011) · Shock · doi:10.1097/shk.0b013e3182168cce · Cited by 155
Self-citationPD-1 Blockage Reverses Immune Dysfunction and Hepatitis B Viral Persistence in a Mouse Animal Model
Tzeng, H.-T., Tsai, H.-F., Liao, H., Lin, Y.-J., Chen, L., Chen, P., & Hsu, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039179 · Cited by 152
Johanns, T., Ertelt, J. M., Rowe, J., & Way, S.-S. Y. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001043 · Cited by 148
Role of PD-1 in regulating acute infections
Brown, K. E., Freeman, G. J., Wherry, E. J., & Sharpe, A. H. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.03.007 · Cited by 147
Interleukin-7 Ameliorates Immune Dysfunction and Improves Survival in a 2-Hit Model of Fungal Sepsis
Unsinger, J., Burnham, C. D., McDonough, J. S., Morre, M., Prakash, P. S., Caldwell, C. C., Dunne, W. M., & Hotchkiss, R. S. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis383 · Cited by 131
Self-citationImmunotherapy for Fungal Infections
Segal, B. H., Kwon‐Chung, J., Walsh, T. J., Klein, B. S., Battiwalla, M., Almyroudis, N. G., Holland, S. M., & Romani, L. R. (2006) · Clinical Infectious Diseases · doi:10.1086/499811 · Cited by 111
Palmer, B. E., Neff, C. P., LeCureux, J., Ehler, A. C., D’Souza, M., Remling‐Mulder, L., Korman, A. J., Fontenot, A. P., & Akkina, R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201108 · Cited by 110
Self-citationVenet, F., Lepape, A., & Monneret, G. (2011) · Critical Care · doi:10.1186/cc10333 · Cited by 96
Immune Effects of Interferon Gamma in Persistent Staphylococcal Sepsis
Nalos, M., Santner‐Nanan, B., Parnell, G. P., Tang, B. M. P., McLean, A. S., & Nanan, R. K. H. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.185.1.110 · Cited by 88
How to Identify Systemic Sepsis-Induced Immunoparalysis
Monneret, G. (2005) · Cited by 82
Ward, P. A. (2011) · JAMA · doi:10.1001/jama.2011.1831 · Cited by 76
Anderson, K. M., Czinn, S. J., Redline, R. W., & Blanchard, T. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5306 · Cited by 70
The PD-1/PD-L1 Pathway in Human Pathology
Saresella, M., Rainone, V., Al‐Daghri, N. M., Clerici, M., & Trabattoni, D. (2012) · Current Molecular Medicine · doi:10.2174/156652412799218903 · Cited by 65
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
CTLA-4 Blockage Increases Resistance to Infection with the Intracellular Protozoan Trypanosoma cruzi
Martins, G. A., Tadokoro, C. E., Silva, R. B., Silva, J. S., & Rizzo, L. V. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4893 · Cited by 51
Surgical critical care: Fungal infections in surgical patients
Lipsett, P. A. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000231883.93001.e0 · Cited by 51
Novel strategies to eliminate persistent viral infections
Martinic, M. M. A., & von Herrath, M. G. (2008) · Trends in Immunology · doi:10.1016/j.it.2007.12.002 · Cited by 32
Immunotherapy for fungal infections
Armstrong-James, D. P. H., & Harrison, T. S. (2012) · Current Opinion in Microbiology · doi:10.1016/j.mib.2012.06.001 · Cited by 32
Cited by
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3552 · Cited by 2,772
Self-citationHotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J.-L. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.45 · Cited by 1,620
Self-citationvan der Poll, T., Shankar-Hari, M., & Wiersinga, W. J. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.012 · Cited by 1,010
Advances in the understanding and treatment of sepsis-induced immunosuppression
Venet, F., & Monneret, G. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.165 · Cited by 981
The immune system’s role in sepsis progression, resolution, and long-term outcome
Delano, M. J., & Ward, P. A. (2016) · Immunological Reviews · doi:10.1111/imr.12499 · Cited by 880
Metadata
- Authors
- Chang, K. C., Burnham, C.-A., Compton, S. M., Rasche, D. P., Mazuski, R., SMcDonough, J., Unsinger, J., Korman, A. J., Green, J. M., & Hotchkiss, R. S.
- Venue
- Critical Care
- Published
- 2013-05-11
- Volume
- 17
- Issue
- 3
- Pages
- R85-R85
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W2163003530
- Cited by
- 281
- References
- 46
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.